Christopher Power

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4852618/publications.pdf

Version: 2024-02-01

235 papers

17,204 citations

66 h-index 19470 122 g-index

240 all docs 240 docs citations

times ranked

240

17903 citing authors

#	Article	IF	CITATIONS
1	Anti-inflammatory role of GM1 and other gangliosides on microglia. Journal of Neuroinflammation, 2022, 19, 9.	3.1	32
2	Intranasal antiâ€caspaseâ€1 therapy preserves myelin and glucose metabolism in a model of progressive multiple sclerosis. Glia, 2021, 69, 216-229.	2.5	10
3	Modeling the Effects of Latency Reversing Drugs During HIV-1 and SIV Brain Infection with Implications for the "Shock and Kill―Strategy. Bulletin of Mathematical Biology, 2021, 83, 39.	0.9	5
4	Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile. Neurological Sciences, 2021, 42, 5241-5247.	0.9	3
5	Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning. Aids, 2021, 35, 1785-1793.	1.0	4
6	Progressive multifocal leukoencephalopathy and Creutzfeldt-Jakob disease: population-wide incidences, comorbidities, costs of care, and outcomes. Journal of NeuroVirology, 2021, 27, 476-481.	1.0	5
7	Plasma microRNAs are associated with domain-specific cognitive function in people with HIV. Aids, 2021, 35, 1795-1804.	1.0	1
8	Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 2021, 65, e0049121.	1.4	9
9	Differential disease phenotypes and progression in relapsing–remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinics. BMC Neurology, 2021, 21, 295.	0.8	4
10	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain, 2021, 144, 3576-3588.	3.7	101
11	Infection of Glia by Human Pegivirus Suppresses Peroxisomal and Antiviral Signaling Pathways. Journal of Virology, 2021, 95, e0107421.	1.5	7
12	Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period. Aids, 2021, 35, 63-72.	1.0	17
13	Long-term consequences of interpersonal violence experiences on treatment engagement and health status in people living with HIV. Aids, 2021, 35, 801-809.	1.0	3
14	Intracellular nickel accumulation induces apoptosis and cell cycle arrest in human astrocytic cells. Metallomics, 2021, 13, .	1.0	4
15	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation. MBio, 2021, 12, e0278421.	1.8	19
16	Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS. Journal of NeuroVirology, 2020, 26, 41-51.	1.0	16
17	Fiery Cell Death: Pyroptosis in the Central Nervous System. Trends in Neurosciences, 2020, 43, 55-73.	4.2	205
18	Sparse Multicategory Generalized Distance Weighted Discrimination in Ultra-High Dimensions. Entropy, 2020, 22, 1257.	1.1	1

#	Article	IF	CITATIONS
19	Lifetime antiretroviral exposure and neurocognitive impairment in HIV. Journal of NeuroVirology, 2020, 26, 743-753.	1.0	26
20	Activation of the executioner caspases-3 and -7 promotes microglial pyroptosis in models of multiple sclerosis. Journal of Neuroinflammation, 2020, 17, 253.	3.1	44
21	The HIV-1 Accessory Protein Vpu Downregulates Peroxisome Biogenesis. MBio, 2020, 11, .	1.8	18
22	Bacterial Peptidoglycan as a Driver of Chronic Brain Inflammation. Trends in Molecular Medicine, 2020, 26, 670-682.	3 . 5	49
23	Use of Primary Human Fetal Astrocytes and Tissue Explants as Ex Vivo Models to Study Zika Virus Infection of the Developing Brain. Methods in Molecular Biology, 2020, 2142, 251-259.	0.4	7
24	HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy. Current Opinion in Virology, 2019, 38, 54-62.	2.6	22
25	Interplay between Zika Virus and Peroxisomes during Infection. Cells, 2019, 8, 725.	1.8	22
26	Absent in melanoma 2 regulates tumor cell proliferation in glioblastoma multiforme. Journal of Neuro-Oncology, 2019, 144, 265-273.	1.4	16
27	Misinterpretation of Study Data. JAMA Neurology, 2019, 76, 113.	4.5	0
28	HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. Cell Death and Differentiation, 2019, 26, 1942-1954.	5.0	11
29	Fibroblast Growth Factor 2 Enhances Zika Virus Infection in Human Fetal Brain. Journal of Infectious Diseases, 2019, 220, 1377-1387.	1.9	23
30	Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2019, 328, 50-59.	1,1	90
31	Empiric neurocognitive performance profile discovery and interpretation in HIV infection. Journal of NeuroVirology, 2019, 25, 72-84.	1.0	16
32	Targeted Elimination of Peroxisomes During Viral Infection: Lessons from HIV and Other Viruses. DNA and Cell Biology, 2018, 37, 417-421.	0.9	9
33	Neurologic disease in feline immunodeficiency virus infection: disease mechanisms and therapeutic interventions for NeuroAIDS. Journal of NeuroVirology, 2018, 24, 220-228.	1.0	14
34	Sarcocystis myopathy in a patient with HIV-AIDS. Journal of NeuroVirology, 2018, 24, 376-378.	1.0	3
35	Cysteinyl Leukotriene Receptor Antagonists Inhibit Migration, Invasion, and Expression of MMP-2/9 in Human Glioblastoma. Cellular and Molecular Neurobiology, 2018, 38, 559-573.	1.7	27
36	Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS. Canadian Journal of Psychiatry, 2018, 63, 329-336.	0.9	21

#	Article	IF	CITATIONS
37	Human Fetal Astrocytes Infected with Zika Virus Exhibit Delayed Apoptosis and Resistance to Interferon: Implications for Persistence. Viruses, 2018, 10, 646.	1.5	47
38	Neurocognitive Impairment and Associated Genetic Aspects in HIV Infection. Current Topics in Behavioral Neurosciences, 2018, 50, 41-76.	0.8	1
39	Human pegivirus†associated leukoencephalitis: Clinical and molecular features. Annals of Neurology, 2018, 84, 781-787.	2.8	15
40	Tumor-to-Lesion Metastasis: Case Report of Carcinoma Metastasis to Multiple Sclerosis Lesion. World Neurosurgery, 2018, 116, 14-17.	0.7	2
41	Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6065-E6074.	3.3	346
42	HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA–455-3p induction. JCl Insight, 2018, 3, .	2.3	28
43	Immune Sensors and Effectors of Health and Disease. , 2017, , 93-105.		2
44	Modeling brain lentiviral infections during antiretroviral therapy in AIDS. Journal of NeuroVirology, 2017, 23, 577-586.	1.0	7
45	Zika Virus Hijacks Stress Granule Proteins and Modulates the Host Stress Response. Journal of Virology, 2017, 91, .	1.5	96
46	Cadmium-induced IL-6 and IL-8 expression and release from astrocytes are mediated by MAPK and NF-κB pathways. NeuroToxicology, 2017, 60, 82-91.	1.4	90
47	MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. Journal of Neuroinflammation, 2017, 14, 55.	3.1	95
48	Host MicroRNAs-221 and -222 Inhibit HIV-1 Entry in Macrophages by Targeting the CD4 Viral Receptor. Cell Reports, 2017, 21, 141-153.	2.9	57
49	A neuropathic pain syndrome associated with hantavirus infection. Journal of NeuroVirology, 2017, 23, 919-921.	1.0	3
50	Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation. Glia, 2017, 65, 1590-1606.	2.5	36
51	Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts. Brain, 2017, 140, 2273-2285.	3.7	134
52	HIV-1 Viral Protein R Activates NLRP3 Inflammasome in Microglia: implications for HIV-1 Associated Neuroinflammation. Journal of NeuroImmune Pharmacology, 2017, 12, 233-248.	2.1	97
53	MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation. Frontiers in Immunology, 2017, 8, 758.	2.2	60
54	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. Retrovirology, 2017, 14, 47.	0.9	57

#	Article	IF	CITATIONS
55	Determinants of risk-taking in HIV-associated neurocognitive disorders Neuropsychology, 2017, 31, 798-810.	1.0	8
56	MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology. PLoS Pathogens, 2017, 13, e1006360.	2.1	65
57	Zika virus inhibits type†interferon production and downstream signaling. EMBO Reports, 2016, 17, 1766-1775.	2.0	252
58	Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. Canadian Journal of Neurological Sciences, 2016, 43, 157-162.	0.3	11
59	Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. Aids, 2016, 30, 2021-2031.	1.0	38
60	Closing in on an infectious etiology of motor neuron disease. Neurology, 2016, 87, 1750-1751.	1.5	1
61	Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. Journal of Neuroscience, 2016, 36, 10683-10695.	1.7	66
62	Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis. Scientific Reports, 2016, 6, 37344.	1.6	85
63	Multifocal inflammatory demyelination in a patient with rheumatoid arthritis and treatment complications. Journal of the Neurological Sciences, 2016, 367, 305-307.	0.3	2
64	Neuroinflammation Preceding and Accompanying Primary Central Nervous System Lymphoma: Case Study and Literature Review. World Neurosurgery, 2016, 88, 692.e1-692.e8.	0.7	15
65	Rapid Multifocal Neurologic Decline in an Immunocompromised Patient. JAMA Neurology, 2016, 73, 226.	4.5	1
66	HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. Aids, 2016, 30, 543-552.	1.0	41
67	Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability. BMC Neurology, 2015, 15, 61.	0.8	13
68	Application of "Omics―Technologies for Diagnosis and Pathogenesis of Neurological Infections. Current Neurology and Neuroscience Reports, 2015, 15, 58.	2.0	4
69	Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). Journal of Clinical and Experimental Neuropsychology, 2015, 37, 733-750.	0.8	13
70	Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder. Molecular and Cellular Biology, 2015, 35, 3684-3700.	1.1	29
71	Human Endogenous Retrovirus-K(II) Envelope Induction Protects Neurons during HIV/AIDS. PLoS ONE, 2014, 9, e97984.	1.1	41
72	Allopregnanolone and neuroinflammation: a focus on multiple sclerosis. Frontiers in Cellular Neuroscience, 2014, 8, 134.	1.8	71

#	Article	IF	Citations
73	The brain and HAART. Current Opinion in HIV and AIDS, 2014, 9, 579-584.	1.5	22
74	Editorial. Current Opinion in HIV and AIDS, 2014, 9, 515-516.	1.5	0
75	Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Multiple Sclerosis Journal, 2014, 20, 1396-1400.	1.4	80
76	Inflammasomes in the CNS. Nature Reviews Neuroscience, 2014, 15, 84-97.	4.9	537
77	Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology, 2014, 11, 35.	0.9	180
78	HIV-1 Nef expression in microglia disrupts dopaminergic and immune functions with associated mania-like behaviors. Brain, Behavior, and Immunity, 2014, 40, 74-84.	2.0	24
79	GABA transport and neuroinflammation are coupled in multiple sclerosis: Regulation of the GABA transporter-2 by ganaxolone. Neuroscience, 2014, 273, 24-38.	1.1	41
80	Nerve growth factor acts through the TrkA receptor to protect sensory neurons from the damaging effects of the HIV-1 viral protein, Vpr. Neuroscience, 2013, 252, 512-525.	1.1	22
81	Inflammasome induction in Rasmussen's encephalitis: cortical and associated white matter pathogenesis. Journal of Neuroinflammation, 2013, 10, 152.	3.1	55
82	Predictors of symptomatic <scp>HIV</scp> â€associated neurocognitive disorders in universal health care. HIV Medicine, 2013, 14, 99-107.	1.0	61
83	Neurosteroidâ€mediated regulation of brain innate immunity in HIV/AIDS: DHEAâ€S suppresses neurovirulence. FASEB Journal, 2013, 27, 725-737.	0.2	39
84	The Regulation of Reactive Changes Around Multiple Sclerosis Lesions by Phosphorylated Signal Transducer and Activator of Transcription. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1135-1144.	0.9	12
85	Differential type 1 interferonâ€regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence. FASEB Journal, 2013, 27, 2829-2844.	0.2	18
86	Metagenomic and Metabolomic Characterization of Rabies Encephalitis: New Insights into the Treatment of an Ancient Disease. Journal of Infectious Diseases, 2013, 207, 1451-1456.	1.9	15
87	Brain Microbial Populations in HIV/AIDS: α-Proteobacteria Predominate Independent of Host Immune Status. PLoS ONE, 2013, 8, e54673.	1.1	127
88	Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Journal of the Neurological Sciences, 2012, 312, 45-51.	0.3	55
89	Delineating HIV-Associated Neurocognitive Disorders Using Transgenic Models: The Neuropathogenic Actions of Vpr. Journal of NeuroImmune Pharmacology, 2012, 7, 319-331.	2.1	25
90	Impact of current antiretroviral therapies on neuroAIDS. Expert Review of Anti-Infective Therapy, 2011, 9, 371-374.	2.0	25

#	Article	IF	CITATIONS
91	Impaired neurosteroid synthesis in multiple sclerosis. Brain, 2011, 134, 2703-2721.	3.7	192
92	Human endogenous retroviruses and multiple sclerosis: Innocent bystanders or disease determinants?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 162-176.	1.8	101
93	Age- and Disease-Dependent HERV-W Envelope Allelic Variation in Brain: Association with Neuroimmune Gene Expression. PLoS ONE, 2011, 6, e19176.	1.1	30
94	Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence. Retrovirology, 2011, 8, 44.	0.9	27
95	Neuromyelitis Optica With Extensive Active Brain Involvement. Archives of Neurology, 2011, 68, 508.	4.9	20
96	Modulation of NKG2D-Mediated Cytotoxic Functions of Natural Killer Cells by Viral Protein R from HIV-1 Primary Isolates. Journal of Virology, 2011, 85, 12254-12261.	1.5	12
97	Proteinase-activated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS. Brain, 2011, 134, 3209-3221.	3.7	26
98	Neuroinflammation and Endoplasmic Reticulum Stress Are Coregulated by Crocin To Prevent Demyelination and Neurodegeneration. Journal of Immunology, 2011, 187, 4788-4799.	0.4	125
99	Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB Journal, 2011, 25, 2211-2220.	0.2	37
100	Viral and Host Genetic Factors. , 2011, , 50-70.		1
101	Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. BMC Neurology, 2010, 10, 44.	0.8	15
102	Domain- and nucleotide-specific Rev response element regulation of feline immunodeficiency virus production. Virology, 2010, 404, 246-260.	1.1	2
103	Regulation of eotaxinâ€3/CCL26 expression in human monocytic cells. Immunology, 2010, 130, 74-82.	2.0	20
104	Hepatitis C Virus Core Protein Induces Neuroimmune Activation and Potentiates Human Immunodeficiency Virus-1 Neurotoxicity. PLoS ONE, 2010, 5, e12856.	1.1	66
105	HIVâ€1 viral protein R causes peripheral nervous system injury associated with ⟨i⟩in vivo⟨ i⟩ neuropathic pain. FASEB Journal, 2010, 24, 4343-4353.	0.2	59
106	MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspaseâ€6 regulates astrocyte survival. FASEB Journal, 2010, 24, 1799-1812.	0.2	79
107	The Human Microbiome in Multiple Sclerosis: Pathogenic or Protective Constituents?. Canadian Journal of Neurological Sciences, 2010, 37, S24-S33.	0.3	11
108	Regulation of Lentivirus Neurovirulence by Lipopolysaccharide Conditioning: Suppression of CXCL10 in the Brain by IL-10. Journal of Immunology, 2010, 184, 1566-1574.	0.4	15

#	Article	lF	CITATIONS
109	Neurologic disease burden in treated HIV/AIDS predicts survival. Neurology, 2010, 75, 1150-1158.	1.5	189
110	Chemokine Proteolytic Processing in HIV Infection: Neurotoxic and Neuroimmune Consequences., 2010, , 149-172.		1
111	Reply to Dr. Garson and Colleagues. AIDS Research and Human Retroviruses, 2009, 25, 379-381.	0.5	2
112	Neurobehavioral Performance in Feline Immunodeficiency Virus Infection: Integrated Analysis of Viral Burden, Neuroinflammation, and Neuronal Injury in Cortex. Journal of Neuroscience, 2009, 29, 8429-8437.	1.7	29
113	Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS. Neurology, 2009, 72, 835-841.	1.5	87
114	NEUROLOGIC IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV/AIDS: OUTCOME AND EPIDEMIOLOGY. Neurology, 2009, 73, 2046-2047.	1.5	0
115	Early Life Exposure to Lipopolysaccharide Suppresses Experimental Autoimmune Encephalomyelitis by Promoting Tolerogenic Dendritic Cells and Regulatory T Cells. Journal of Immunology, 2009, 183, 298-309.	0.4	58
116	Dehydroepiandrosterone sulphate improves cholestasisâ€associated fatigue in bile duct ligated rats. Neurogastroenterology and Motility, 2009, 21, 1319-1325.	1.6	16
117	Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Medicine, 2009, 10, 246-252.	1.0	80
118	Dual lentivirus infection potentiates neuroinflammation and neurodegeneration: viral copassage enhances neurovirulence. Journal of NeuroVirology, 2009, 15, 139-152.	1.0	7
119	CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB Journal, 2009, 23, 2928-2941.	0.2	39
120	Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends in Neurosciences, 2009, 32, 88-100.	4.2	92
121	NeuroAIDS: An Evolving Epidemic. Canadian Journal of Neurological Sciences, 2009, 36, 285-295.	0.3	54
122	NeuroAIDS: a watershed for mental health and nervous system disorders. Journal of Psychiatry and Neuroscience, 2009, 34, 83-5.	1.4	10
123	Acute Disseminated Encephalomyelitis: Clinical and Pathogenesis Features. Neurologic Clinics, 2008, 26, 759-780.	0.8	95
124	HIV Infection of the Central Nervous System: Clinical Features and Neuropathogenesis. Neurologic Clinics, 2008, 26, 799-819.	0.8	127
125	Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and βâ€arrestinâ€i in monocytoid cells. FASEB Journal, 2008, 22, 786-796.	0.2	45
126	Emerging Issues in Neurovirology: New Viruses, Diagnostic Tools, and Therapeutics. Neurologic Clinics, 2008, 26, 855-864.	0.8	2

#	Article	IF	Citations
127	Preface. Neurologic Clinics, 2008, 26, xiii-xv.	0.8	O
128	HIV-1 Vpr Causes Neuronal Apoptosis and In Vivo Neurodegeneration. Journal of Neuroscience, 2007, 27, 3703-3711.	1.7	126
129	The Human Endogenous Retrovirus Envelope Glycoprotein, Syncytin-1, Regulates Neuroinflammation and Its Receptor Expression in Multiple Sclerosis: A Role for Endoplasmic Reticulum Chaperones in Astrocytes. Journal of Immunology, 2007, 179, 1210-1224.	0.4	123
130	West Nile Virus-Induced Neuroinflammation: Glial Infection and Capsid Protein-Mediated Neurovirulence. Journal of Virology, 2007, 81, 10933-10949.	1.5	105
131	Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial. PLOS Clinical Trials, 2007, 2, e13.	3.5	46
132	Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain, 2007, 130, 2011-2023.	3.7	37
133	Central Nervous System Viral Infections: Clinical Aspects and Pathogenic Mechanisms. , 2007, , 485-499.		2
134	Proteinase-Activated Receptor-2 Exerts Protective and Pathogenic Cell Type-Specific Effects in Alzheimer's Disease. Journal of Immunology, 2007, 179, 5493-5503.	0.4	53
135	NeuroAIDS in West Africa: A Full Circle. Canadian Journal of Neurological Sciences, 2007, 34, 118-119.	0.3	13
136	Comparative Expression of Human Endogenous Retrovirus-W Genes in Multiple Sclerosis. AIDS Research and Human Retroviruses, 2007, 23, 1251-1256.	0.5	58
137	NEUROLOGICAL DISORDERS ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION. , 2007, , 1261-1272.		1
138	Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation. Journal of NeuroVirology, 2007, 13, 173-184.	1.0	25
139	Quantitative Analysis of Human Endogenous Retrovirus-Wenvin Neuroinflammatory Diseases. AIDS Research and Human Retroviruses, 2006, 22, 1253-1259.	0.5	44
140	Lentivirus envelope protein exerts differential neuropathogenic effects depending on the site of expression and target cell. Virology, 2006, 348, 260-276.	1.1	10
141	Regulation of neural cell survival by HIV-1 infection. Neurobiology of Disease, 2006, 21, 1-17.	2.1	85
142	Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor–mediated neurotoxicity. Annals of Neurology, 2006, 59, 816-824.	2.8	131
143	Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. Aids, 2006, 20, 2005-2009.	1.0	20
144	Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. Journal of Experimental Medicine, 2006, 203, 425-435.	4.2	145

#	Article	IF	CITATIONS
145	CD8+ Lymphocyte-Mediated Injury of Dorsal Root Ganglion Neurons during Lentivirus Infection: CD154-Dependent Cell Contact Neurotoxicity. Journal of Neuroscience, 2006, 26, 3396-3403.	1.7	19
146	HIV and Other Lentiviral Infections Cause Defects in Neutrophil Chemotaxis, Recruitment, and Cell Structure: Immunorestorative Effects of Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Immunology, 2006, 177, 6405-6414.	0.4	35
147	Proteolytic processing of SDF-1Â reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19182-19187.	3.3	97
148	Undetectable Cerebrospinal Fluid HIV RNA and β-2 Microglobulin Do Not Indicate Inactive AIDS Dementia Complex in Highly Active Antiretroviral Therapy-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 426-429.	0.9	58
149	Aberrant cortical neurogenesis in a pediatric neuroAIDS model: neurotrophic effects of growth hormone. Aids, 2005, 19, 1781-1791.	1.0	29
150	HIV-Related Neurological Syndromes Reduce Health-Related Quality of Life. Canadian Journal of Neurological Sciences, 2005, 32, 201-204.	0.3	41
151	Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology, 2005, 334, 178-193.	1.1	61
152	RON-regulated innate immunity is protective in an animal model of multiple sclerosis. Annals of Neurology, 2005, 57, 883-895.	2.8	38
153	Proteinase-Activated Receptor-2 Induction by Neuroinflammation Prevents Neuronal Death during HIV Infection. Journal of Immunology, 2005, 174, 7320-7329.	0.4	92
154	Lentivirus Infection Causes Neuroinflammation and Neuronal Injury in Dorsal Root Ganglia: Pathogenic Effects of STAT-1 and Inducible Nitric Oxide Synthase. Journal of Immunology, 2005, 175, 1118-1126.	0.4	39
155	The Impact of Neuropsychological Impairment and Depression on Health-Related Quality of Life in HIV-Infection. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 1-15.	0.8	46
156	Human immunodeficiency virus type 1 genetic diversity in the nervous system: Evolutionary epiphenomenon or disease determinant?. Journal of NeuroVirology, 2005, 11, 107-128.	1.0	44
157	HIV-1 Infection and Cell Death in the Nervous System. , 2005, , 381-403.		O
158	RON Receptor Tyrosine Kinase, a Negative Regulator of Inflammation, Inhibits HIV-1 Transcription in Monocytes/Macrophages and Is Decreased in Brain Tissue from Patients with AIDS. Journal of Immunology, 2004, 173, 6864-6872.	0.4	26
159	Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. Journal of NeuroVirology, 2004, 10, 113-117.	1.0	20
160	Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. Journal of NeuroVirology, 2004, 10, 113-117.	1.0	1
161	Human endogenous retrovirus glycoprotein–mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nature Neuroscience, 2004, 7, 1088-1095.	7.1	343
162	The promise of minocycline in neurology. Lancet Neurology, The, 2004, 3, 744-751.	4.9	465

#	Article	IF	Citations
163	Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology, 2004, 329, 302-318.	1.1	158
164	Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. Journal of NeuroVirology, 2004, 10, 113-117.	1.0	24
165	A1 Adenosine Receptor Upregulation and Activation Attenuates Neuroinflammation and Demyelination in a Model of Multiple Sclerosis. Journal of Neuroscience, 2004, 24, 1521-1529.	1.7	297
166	Peripheral neuropathy in lentivirus infection. Aids, 2004, 18, 1241-1250.	1.0	47
167	Human immunodeficiency virus type 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector. Virology, 2003, 309, 61-74.	1.1	13
168	Proteinase-activated receptor expression and function in the brain. Drug Development Research, 2003, 60, 51-57.	1.4	1
169	Interleukin-1? promotes oligodendrocyte death through glutamate excitotoxicity. Annals of Neurology, 2003, 53, 588-595.	2.8	228
170	Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Annals of Neurology, 2003, 53, 731-742.	2.8	334
171	Growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression. Annals of Neurology, 2003, 54, 605-614.	2.8	60
172	Proteinase-activated receptors in the nervous system. Nature Reviews Neuroscience, 2003, 4, 981-990.	4.9	123
173	HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nature Neuroscience, 2003, 6, 1064-1071.	7.1	295
174	In Vivo Impairment of Neutrophil Recruitment during Lentivirus Infection. Journal of Immunology, 2003, 171, 4801-4808.	0.4	33
175	Fatigue in HIV/AIDS is Associated With Depression and Subjective Neurocognitive Complaints but not Neuropsychological Functioning. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 201-215.	0.8	67
176	Human Immunodeficiency Virus Type 1 Envelope-Mediated Neuronal Death: Uncoupling of Viral Replication and Neurotoxicity. Journal of Virology, 2003, 77, 6899-6912.	1.5	48
177	Up-Regulation of Proteinase-Activated Receptor 1 Expression in Astrocytes During HIV Encephalitis. Journal of Immunology, 2003, 170, 2638-2646.	0.4	115
178	Feline Immunodeficiency Virus Xenoinfection: the Role of Chemokine Receptors and Envelope Diversity. Journal of Virology, 2002, 76, 3626-3636.	1.5	34
179	Lentiviral Neuropathogenesis: Comparative Neuroinvasion, Neurotropism, Neurovirulence, and Host Neurosusceptibility. Journal of Virology, 2002, 76, 7923-7931.	1.5	58
180	Envelope Gene-Mediated Neurovirulence in Feline Immunodeficiency Virus Infection: Induction of Matrix Metalloproteinases and Neuronal Injury. Journal of Virology, 2002, 76, 2622-2633.	1.5	37

#	Article	IF	CITATIONS
181	Progress in Clinical Neurosciences: The Neuropathogenesis of HIV Infection: Host-Virus Interaction and the Impact of Therapy. Canadian Journal of Neurological Sciences, 2002, 29, 19-32.	0.3	56
182	HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. Aids, 2002, 16, 1905-1914.	1.0	39
183	Neurovirulence depends on virus input titer in brain in feline immunodeficiency virus infection: Evidence for activation of innate immunity and neuronal injury. Journal of NeuroVirology, 2002, 8, 420-431.	1.0	27
184	Retroviral diseases of the nervous system: pathogenic host response or viral gene-mediated neurovirulence?. Trends in Neurosciences, 2001, 24, 162-169.	4.2	45
185	Neurocognitive Symptoms and Impairment in an HIV Community Clinic. Canadian Journal of Neurological Sciences, 2001, 28, 228-231.	0.3	23
186	Encephalopathy with Staphylococcal Endocarditis: Multiple Neuropathological Findings. Canadian Journal of Neurological Sciences, 2001, 28, 260-264.	0.3	11
187	Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor-α Expression Is Neuroprotective After Intracerebral Hemorrhage. Stroke, 2001, 32, 240-248.	1.0	146
188	Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics, 2001, 3, 145-151.	0.7	40
189	Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Annals of Neurology, 2001, 49, 650-658.	2.8	98
190	Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Annals of Neurology, 2001, 49, 727-735.	2.8	138
191	Monocyte activation and differentiation augment human endogenous retrovirus expression: Implications for inflammatory brain diseases. Annals of Neurology, 2001, 50, 434-442.	2.8	186
192	HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Annals of Neurology, 2001, 49, 230-241.	2.8	125
193	Human Immunodeficiency Virus Type 1 Clade A and D Neurotropism: Molecular Evolution, Recombination, and Coreceptor Use. Virology, 2001, 283, 19-30.	1.1	27
194	Metalloproteinases in biology and pathology of the nervous system. Nature Reviews Neuroscience, 2001, 2, 502-511.	4.9	946
195	Xenoinfection of nonhuman primates by feline immunodeficiency virus. Current Biology, 2001, 11, 1109-1113.	1.8	18
196	Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1. Journal of Biological Chemistry, 2001, 276, 43503-43508.	1.6	576
197	HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. Aids, 2001, 15, 747-751.	1.0	47
198	Neuroimmune and neurovirological aspects of human immunodeficiency virus infection. Advances in Virus Research, 2001, 56, 389-433.	0.9	31

#	Article	IF	Citations
199	Aboriginals with multiple sclerosis. Neurology, 2001, 56, 317-323.	1.5	109
200	Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Annals of Neurology, 2001, 49, 650-8.	2.8	38
201	AIDS- and non–AIDS-related PML association with distinct p53 polymorphism. Neurology, 2000, 54, 743-743.	1.5	102
202	Autopsy Study of HIV-1–Positive and H IV-1–Negative Adult Medical Patients in Nairobi, Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 23-29.	0.9	141
203	Lentivirus Infection in the Brain Induces Matrix Metalloproteinase Expression: Role of Envelope Diversity. Journal of Virology, 2000, 74, 7211-7220.	1.5	98
204	Paroxysmal dyskinesias in patients with HIV infection. Neurology, 1999, 52, 109-109.	1.5	61
205	Antisense Oligodeoxynucleotides Targeting Internal Exon Sequences Efficiently Regulate TNF-α Expression. Oligonucleotides, 1999, 9, 135-144.	4.4	9
206	Primary Headaches in HIV-Infected Patients. Headache, 1999, 39, 3-10.	1.8	51
207	Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Annals of Neurology, 1999, 45, 633-639.	2.8	62
208	Three sample preparation protocols for polymerase chain reaction based detection of Cryptosporidium parvum in environmental samples. Journal of Microbiological Methods, 1999, 35, 65-71.	0.7	46
209	V3 Recombinants Indicate a Central Role for CCR5 as a Coreceptor in Tissue Infection by Human Immunodeficiency Virus Type 1. Journal of Virology, 1999, 73, 2350-2358.	1.5	75
210	Productive Infection of Human Peripheral Blood Mononuclear Cells by Feline Immunodeficiency Virus: Implications for Vector Development. Journal of Virology, 1999, 73, 2491-2498.	1.5	56
211	Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. Annals of Neurology, 1998, 44, 391-394.	2.8	57
212	Parkinsonism with HIV infection. Movement Disorders, 1998, 13, 684-689.	2.2	143
213	Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity. Journal of NeuroVirology, 1998, 4, 387-393.	1.0	52
214	HIV-1 Tat Molecular Diversity and Induction of TNF- $\hat{l}\pm$: Implications for HIV-Induced Neurological Disease. NeuroImmunoModulation, 1998, 5, 184-192.	0.9	79
215	Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3117-3121.	3.3	552
216	Neuronal Death Induced by Brain-Derived Human Immunodeficiency Virus Type 1 Envelope Genes Differs between Demented and Nondemented AIDS Patients. Journal of Virology, 1998, 72, 9045-9053.	1.5	170

#	Article	IF	Citations
217	Neurovirulence in Feline Immunodeficiency Virus-Infected Neonatal Cats Is Viral Strain Specific and Dependent on Systemic Immune Suppression. Journal of Virology, 1998, 72, 9109-9115.	1.5	62
218	Remission of Progressive Multifocal Leukoencephalopathy Following Splenectomy and Antiretroviral Therapy in a Patient with HIV Infection. New England Journal of Medicine, 1997, 336, 661-662.	13.9	71
219	The Tat Protein of HIV-1 Induces Tumor Necrosis Factor-α Production. Journal of Biological Chemistry, 1997, 272, 22385-22388.	1.6	208
220	Feline immunodeficiency virus causes increased glutamate levels and neuronal loss in brain. Neuroscience, 1997, 77, 1175-1185.	1.1	53
221	Rabies viruses infect primary cultures of murine, feline, and human microglia and astrocytes. Archives of Virology, 1997, 142, 1011-1019.	0.9	31
222	AIDS dementia complex with generalized myoclonus. Movement Disorders, 1997, 12, 593-597.	2.2	36
223	Interactions of the human immunodeficiency virus with astrocytes. Journal of Computer - Aided Molecular Design, 1996, 5, 30-42.	1.0	3
224	Major histocompatibility complex Class I expression in oligodendrocytes induces hypomyelination in transgenic mice. Journal of Neuroscience Research, 1996, 44, 165-173.	1.3	27
225	HIV-1 Associated Dementia: Clinical Features and Pathogenesis. Canadian Journal of Neurological Sciences, 1995, 22, 92-100.	0.3	91
226	HIV Dementia Scale: A Rapid Screening Test. Journal of Acquired Immune Deficiency Syndromes, 1995, 8, 273-278.	0.3	302
227	Distinct HIV-1 env Sequences Are Associated with Neurotropism and Neurovirulence. Current Topics in Microbiology and Immunology, 1995, 202, 89-104.	0.7	69
228	Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. Journal of Virology, 1994, 68, 4643-4649.	1.5	268
229	Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dememtia. Annals of Neurology, 1993, 33, 576-582.	2.8	444
230	Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood-brain barrier. Annals of Neurology, 1993, 34, 339-350.	2.8	345
231	A model of human immunodeficiency virus encephalitis in scid mice Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8658-8662.	3.3	126
232	Long-term psychosocial sequelae of chronic physical disorders in childhood. Pediatrics, 1993, 91, 1131-6.	1.0	43
233	Encephalopathy in Liver Transplantation: Neuropathology and CMV Infection. Canadian Journal of Neurological Sciences, 1990, 17, 378-381.	0.3	30
234	Cytomegalovirus and Rasmussen's encephalitis. Lancet, The, 1990, 336, 1282-1284.	6.3	136

ARTICLE IF CITATIONS

235 Neuro-inflammation., 0, , 245-260. 1